Castle Biosciences (CSTL) Competitors

Celcuity (NASDAQ:CELC) and Castle Biosciences (NASDAQ:CSTL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, community ranking, risk, analyst recommendations, institutional ownership, valuation and earnings.

Does the media refer more to CELC or CSTL?

In the previous week, Castle Biosciences had 6 more articles in the media than Celcuity. MarketBeat recorded 8 mentions for Castle Biosciences and 2 mentions for Celcuity. Celcuity's average media sentiment score of -1.11 beat Castle Biosciences' score of -1.90 indicating that Castle Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Very Negative
Castle Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Is CELC or CSTL more profitable?

Celcuity has a net margin of 0.00% compared to Celcuity's net margin of -39.32%. Celcuity's return on equity of -19.50% beat Castle Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-49.14%	-35.52%
Castle Biosciences	-39.32%	-19.50%	-17.40%

Which has more risk & volatility, CELC or CSTL?

Celcuity has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Comparatively, Castle Biosciences has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500.

Do institutionals and insiders believe in CELC or CSTL?

63.3% of Celcuity shares are held by institutional investors. Comparatively, 85.8% of Castle Biosciences shares are held by institutional investors. 24.3% of Celcuity shares are held by insiders. Comparatively, 7.7% of Castle Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Which has preferable earnings & valuation, CELC or CSTL?

Celcuity has higher earnings, but lower revenue than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than Celcuity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$40.37M	-$2.73	-5.41
Castle Biosciences	$192.01M	2.83	-$67.14M	-$2.84	-7.10

Does the MarketBeat Community favor CELC or CSTL?

Celcuity received 241 more outperform votes than Castle Biosciences when rated by MarketBeat users. Likewise, 66.25% of users gave Celcuity an outperform vote while only 61.11% of users gave Castle Biosciences an outperform vote.

Company	Underperform	Outperform
Celcuity	Outperform Votes 318 66.25%	Underperform Votes 162 33.75%
Castle Biosciences	Outperform Votes 77 61.11%	Underperform Votes 49 38.89%

Do analysts rate CELC or CSTL?

Celcuity presently has a consensus target price of $25.00, indicating a potential upside of 67.22%. Castle Biosciences has a consensus target price of $32.29, indicating a potential upside of 60.07%. Given Castle Biosciences' higher probable upside, equities research analysts clearly believe Celcuity is more favorable than Castle Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Castle Biosciences	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Celcuity and Castle Biosciences tied by winning 8 of the 16 factors compared between the two stocks.